



Offering smarter treatment decisions for lung cancer patients

Q1
2016

Med BioGene Inc. MBI-TSX Venture

- ✓ New management team led by proactive shareholder focused on dividend payment
- ✓ Near-term commercialization potential for leading lung cancer treatment prognostic test
- ✓ Compelling valuation, excellent liquidity

Med BioGene Inc. www.medbiogene.com is a Vancouver-based life science company.

It manages the license and rights to GeneFx® Lung – a genomic-based prognostic test that allows patients, doctors and insurers to make more informed decisions on whether chemotherapy will be an effective treatment method for certain types of lung cancers.

In September of 2014, after a long proxy battle, dissident shareholder Dr. Iain Weir-Jones, a Vancouver-based mining engineer, led a slate of four persons who were elected to the board of directors and replaced previous management. The new management team has reduced the burn rate by 80%, has sufficient working capital until Q4 2016, and has markedly improved shareholder communications.

As the new CEO of MedBiogene, and as an investor whose family controls about 13 million shares, Dr. Weir-Jones' objective is to pay a dividend to MBI shareholders by the end of fiscal 2016.

Symbol	MBI	Market Capitalization	\$7.36 million
Share Outstanding (Basic)	86.6 million	52 week range (High/Low)	\$0.105 - \$0.03
Share Price Dec 31st	\$0.085	Management & Board Holdings	14%

What is GeneFx® Lung?

- A genomic-based (DNA) prognostic test procedure for early-stage, non-small-cell lung cancer. Lung cancer kills more people than breast, prostate and colon cancer combined.
- Benefits: expected to improve the standard of care and save health care costs by identifying:
 - Higher-Risk patients with aggressive tumours who may require chemotherapy
 - Lower-Risk patients with less aggressive tumours who may not require, or may be harmed by, chemotherapy
- Potential \$500 million market opportunity in Canada, the United States and Europe – providing personalized health care that empowers cancer patients and their physicians to make better-informed and more individualized treatment decisions through the most comprehensive and personalized tumour profiling available.
- Strong partnership with Helomics™ Corporation - a leading US-based private equity backed company, www.helomics.com
- Clear Reimbursement strategy: Paves the way for third party payers to reimburse Helomics™ for the GeneFx® Lung test.

Milestones & Catalysts

Q4/15



Confirmation of Third-Party Payer for the use of GeneF^x® Lung diagnostic tests

Med BioGene Inc. confirmed on December 15th, 2015, that its licensee, Helomics, has advised the company that logistical procedures necessary for the first commercial application of GeneF^x Lung will commence in the first quarter of 2016. In addition to this commercial premarket access agreement, Helomics anticipates announcing that a second major U.S. health care provider has approved the use of the GeneF^x Lung diagnostic test for its members. The logistical requirements for the commencement of commercial testing for this provider will start in the second quarter of 2016.

Q2/16

Initial Helomics™ sales of GeneF^x® Lung trigger first milestone payment to Med BioGene Inc.

Q3/16

Helomics™ sales of GeneF^x® Lung trigger second milestone payment to Med BioGene Inc.

Three Key Reasons to Own Med BioGene



1 Strong Leadership: Dr. Weir-Jones is a highly successful Vancouver-based businessman. He is Chairman of the Weir-Jones Group of Companies (www.weir-jones.com), a leading Canadian specialized engineering firm that has worked for private and government clients in more than 55 countries since 1971. His family are long term investors in MBI owning about 13 million shares. Dr. Weir-Jones is a UK-trained mining engineer with a Ph.D in Geomechanics from the University of Newcastle. Under his

leadership, Med BioGene has become a leaner, more efficient and focused public company with a strong capital base and the singular objective of delivering a dividend to shareholders by the end of 2016.

2 Large Market Opportunity: GeneF^x® Lung's total available estimated market is \$1.3 billion*. Lung cancer kills more people than breast, prostate and colon cancer combined. GeneF^x® Lung is targeted for use with early non-small cell lung cancer, approximately one-third of all lung cancer cases, with 420,000 new cases annually in North America, Asia and Europe.

3 Partnership with Helomics™ (formerly Precision Therapeutics): Helomics™ is a top-tier, molecular diagnostics company, based in Pittsburgh, with initial private equity support from strong investors including Bain, Adams Capital, Longitude Capital and Quaker BioVentures; and most recently from Healthcare Royalty Partners, www.healthcarepartners.com. Helomics™ is a leader in the developing field of personalized medicine. Med BioGene completed the Helomics™ partnership in April of 2011. Upon completion MBI received \$2.3 million with \$1 million in future milestone payments, and a royalty on gross sales in the high single digits. Helomics™ is responsible for all future costs associated with the development and commercialization of GeneF^x® Lung.

**This estimate of the total potential market size is based upon medical data which shows that there are approximately 1.5 million new cases of lung cancer diagnosed annually. Of these ~ 30% are Type I and II NSCLC, identifiable by the genomic based GeneF^x® Lung prognostic test at a projected cost/test of ~ USD \$3,000.*

Contact

**Iain Weir-Jones, Ph.D.,
P.Eng., FGS**

Chairman

598 East Kent Ave S.
Vancouver, BC, Canada
V5X 4V6

Ph: (604) 732-7332
Fx: (604) 732-4801

Email: iainw@medbiogene.com

Investor Relations:

**Rick Peterson
Peterson Capital**

604-249-7890

rick@petersoncapital.ca

www.petersoncapital.ca

Disclaimer and Forward-looking Statements

This fact sheet has been prepared from information provided by Med BioGene Inc. ("the Company") and contains forward-looking statements about the Company, its future performance, strategies or prospects, and possible future action. The words "may", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve inherent risks and uncertainties, both about the Company and general economic factors, so it is possible that predictions, forecasts, projections and other forward-looking statements will not be achieved. We caution you not to place undue reliance on these statements as a number of important factors could cause actual events or results to differ materially from those expressed or implied in any forward-looking statement made in relation to the Company. These factors include, but are not limited to, general economic, political and market factors in Canada, the United States and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, technological changes, changes in laws and regulations, judicial or regulatory judgements, legal proceedings and catastrophic events. The above list of important factors that may affect future results is not exhaustive. Before making any investment decisions, we encourage you to consider these and other factors carefully. All opinions contained in forward-looking statements are subject to change without notice and are provided in good faith but without legal responsibility.